The global amyloidosis therapeutics market is experiencing strong growth, valued at $2.95 billion in 2024 and expected to reach $6.37 billion by 2033 with a 9.20% CAGR. Growth is driven by accelerating ATTR cardiomyopathy diagnosis through imaging technologies, rapid uptake of disease-modifying therapies in North America, and expanded reimbursement in emerging markets like China and Brazil. Five core compounds dominate the market, with chemotherapy remaining the cost-effective backbone for AL amyloidosis treatment.

Alnylam Pharmaceuticals announced its 'Alnylam 2030' five-year roadmap, targeting durable global leadership in transthyretin (TTR) diseases with plans to launch nucresiran by 2028-2030. The company projects 2026 net product revenue of $4.9-5.3 billion (71% growth), significantly above Street estimates, with TTR franchise expected to reach $4.4-4.7 billion. However, shares fell 10% on Monday despite strong guidance, as 2025 revenues narrowly missed expectations.

Scenic Biotech announced a license and research agreement with Ono Pharmaceutical to utilize its Cell-Seq platform for discovering novel therapeutic targets. This marks Scenic's fourth major pharmaceutical collaboration, joining existing partnerships with Genentech, Bristol Myers Squibb, and Alnylam.

Vertiv Holdings, an AI infrastructure company providing data center power and cooling solutions, has a 71% probability of being added to the S&P 500 in Q1 2026 according to prediction markets, significantly higher than competitors. The company has surged over 1,047% in less than three years with strong financial performance, including 29% year-over-year revenue growth and a robust $9.5 billion backlog.

Nasdaq announced its annual Nasdaq-100 Index reconstitution, adding six companies and removing six others, effective December 22, 2025. The changes reflect the dynamic composition of leading non-financial companies across various sectors.

Alnylam Pharmaceuticals, a biotech company focused on RNA interference (RNAi) therapies, has shown significant growth since its 2004 IPO. The company has multiple approved drugs for rare diseases and a promising pipeline of potential treatments across various medical conditions.

Alnylam Pharmaceuticals reported strong Q3 earnings, beating analyst expectations with a 149% year-over-year sales increase and raised fiscal 2025 sales guidance. The company showed promising results for its drug Amvuttra in treating transthyretin amyloid cardiomyopathy.

The article discusses how AI is transforming drug development, potentially reducing research cycles from 10-15 years to 3-6 years. BlackRock Health Sciences Term Trust offers an 8.8% dividend and trades at a 13% discount, with potential for growth as AI accelerates pharmaceutical research.

Novo Nordisk presented Phase 2 trial results for Coramitug, an antibody targeting transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The drug showed a statistically significant reduction in heart failure biomarker NT-proBNP and was well-tolerated.

Novartis showcased new research data across its Cardiovascular, Renal, and Metabolic disease portfolio, presenting 33 abstracts at ASN Kidney Week and AHA Scientific Sessions, highlighting clinical trial results for treatments in kidney and heart conditions.

BlackRock Health Sciences Term Trust (BMEZ) recently cut its dividend, but still offers a 9.2% monthly yield. The fund focuses on healthcare innovators that could benefit from potential policy changes, with top holdings in biotech and medical technology companies.

Scenic Biotech appointed Dr. Roland W. Bürli as Chief Scientific Officer to lead development of modifier therapies for neurodegenerative and metabolic diseases, leveraging the company's Cell-Seq platform.